Shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) have received a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the firm. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $30.80.

A number of equities research analysts have recently weighed in on the company. Mizuho restated a “top pick” rating and set a $26.00 target price on shares of Adamas Pharmaceuticals in a research report on Wednesday, March 15th. Zacks Investment Research downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, February 16th.

In other news, CEO Gregory T. Went sold 2,807 shares of the business’s stock in a transaction on Tuesday, March 21st. The stock was sold at an average price of $17.03, for a total transaction of $47,803.21. Following the completion of the sale, the chief executive officer now owns 166,526 shares in the company, valued at $2,835,937.78. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 4,256 shares of company stock valued at $72,480. 31.79% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in the company. Citadel Advisors LLC bought a new stake in shares of Adamas Pharmaceuticals during the third quarter worth approximately $219,000. Ardsley Advisory Partners bought a new stake in shares of Adamas Pharmaceuticals during the third quarter worth approximately $246,000. GAM Holding AG bought a new stake in shares of Adamas Pharmaceuticals during the third quarter worth approximately $328,000. Russell Investments Group Ltd. bought a new stake in shares of Adamas Pharmaceuticals during the fourth quarter worth approximately $469,000. Finally, Opus Point Partners Management LLC boosted its stake in shares of Adamas Pharmaceuticals by 32.7% in the third quarter. Opus Point Partners Management LLC now owns 60,000 shares of the specialty pharmaceutical company’s stock worth $985,000 after buying an additional 14,802 shares during the period. 75.44% of the stock is owned by institutional investors and hedge funds.

Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) traded down 0.32% during midday trading on Monday, reaching $15.62. The company’s stock had a trading volume of 150,060 shares. Adamas Pharmaceuticals has a 52-week low of $12.10 and a 52-week high of $19.50. The company’s market capitalization is $347.06 million. The stock has a 50 day moving average price of $17.08 and a 200-day moving average price of $16.26.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Tuesday, February 28th. The specialty pharmaceutical company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.12. The company earned $0.04 million during the quarter, compared to the consensus estimate of $0.17 million. Adamas Pharmaceuticals had a negative return on equity of 38.31% and a negative net margin of 5,267.99%. The firm’s quarterly revenue was down 92.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.58) earnings per share. Equities research analysts expect that Adamas Pharmaceuticals will post ($3.26) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Brokerages Set Adamas Pharmaceuticals Inc (ADMS) Price Target at $30.80” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

5 Day Chart for NASDAQ:ADMS

Receive News & Ratings for Adamas Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.